Dow Jones 10485.65 +0.00 6:16 am PST, March 29, 2005  NASDAQ 1992.52 +0.00 For info, visit access.smallcapnetwork.com S & P 500 1174.28 +0.00 Change your subscription status here Russell 2000 615.12 +0.00 VOLUME 05: ISSUE 24  Feature: Biocurex Signs Abbott Labs - Licensing Deal Done. Patience rewarded. Significant milestone achieved. Those two phrases encapsulate the importance of the joint announcement made today (release below) by biotech Biocurex (BOCX.PK) of the completion of a deal granting world-wide, semi-exclusive rights for its RECAF? technology to healthcare giant Abbott Laboratories (NYSE: ABT).  Abbott has 60,000 employees, markets its products in more than 130 countries and posted almost $20 billion in annual sales in the past year. Since we first brought Biocurex to the readership in October 2003 at 17 cents, the company has asked for investors' patience and worked diligently to attract and sign significant partners with whom to license its cancer detection technology. Today's announcement with behemoth Abbott Labs is a watershed for Biocurex and, we believe heralds the beginning of more deals as well as providing further validation of Biocurex's cancer detecting RECAF? technology. Tuesday, in the joint Abbott/Biocurex press release the former announced that it "obtains worldwide, semi-exclusive rights to commercialize products using Biocurex's RECAF? technology". The release further states that the work done by Biocurex may be "useful in the development of new cancer diagnostic tests". Now that's impressive. A large cap, quality partner who has the money and R&D muscle to advance RECAF's? importance as a tumor marker for the early detection of several types of cancer including prostate, breast, colorectal and lung. It's difficult to quantify the trading impact of today's announcement within short-term technical guidelines. For those who hold shares, if there is a move up, a partial sale may be warranted to lower a cost base. For anyone who wades in to purchase, ensure that stop losses are in place as we suspect there will be significant volatility. Trade strategically is our best suggestion at this point. A core position should be maintained for the long term. The shares have already moved up on deal speculation--especially on message boards such as Raging Bull-- over the past couple of weeks to close at $1.89, Monday. Depending on how the shares trade, the next resistance level looks to be around $2.60. If that level is breached convincingly, the shares could eventually try and retest the $3.90 level from last April. It won't be dull, no matter what happens.  All we can say without fear of contradiction is that trading from Tuesday's opening bell will be heavy. We suspect that there has been some shorting going on recently, and if there is a push in the BOCX stock price, covering may well add to the volatility as the naysayers get spanked, The quote for BOCX shares is here: http://www.pinksheets.com/quote/quote.jsp?symbol=BOCX Yes, this is an extremely BIG deal. From the release:  "Abbott's goal is to further develop this technology, incorporating it into future tests on our ARCHITECT® system, for use in cancer diagnosis and monitoring". ARCHITECT® is Abbott's series of proprietary testing systems used for specific diagnostic regimens. By example, one of these regimens, the ARCHITECT®  ci8200 system is described thusly: Combining immunoassay and clinical chemistry on one integrated platform, the ci8200 system runs up to 200 immunoassay tests and up to 1200 clinical chemistry tests an hour. By consolidating both immunoassay and clinical chemistry testing capabilities, the ci8200 helps improve laboratory productivity and efficiency. Once royalties begin to flow to Biocurex, the potential revenue generation, we believe, will be significant. Three words: Deal = Enhanced Validation. This deal is obviously a major corporate development for Biocurex. As well, in our opinion, the enhanced validation a deal such as this affords its technologies within the medical/diagnostic and pharmaceutical communities are likely beyond price.  Abbott apparently realizes, as does Biocurex, that this early cancer detection technology could well save a significant number of lives. Specific details of the deal were not disclosed, but does include upfront fees, development milestones and royalties on any product sales. As Abbott is a worldwide leader in diagnostic testing, the potential for Biocurex is, to say the least, compelling. As well, in our opinion, this development should both advance the company's current licensing discussions as well as bring further significant potential partners to the table. Semi's the word. That brings us to the term 'semi-exclusive' within Tuesday's release. Biocurex, for obvious reasons, is loath to grant exclusivity to any one company. Top-tier companies such as Abbott historically tend to want exclusivity. The fact that Abbott entered into a semi-exclusive arrangement, leaving Biocurex the right to enter into licensing arrangements with other companies, we believe, evidences the potential it sees in the technology and further enforces RECAF's? viability. The other factor is that with Abbott on board to advance the RECAF? technology, it allows Biocurex to focus and advance its technologies in the cancer imaging and therapy areas. It's only just begun... Biocurex, through all its travails over the last year has never lost sight of the amazing potential of its technology for the early detection of cancer as well as the attendant cost savings to the healthcare sector. You may recall that just about a year ago, the shares charged up to $3.90 a share on daily volume in the tens of millions. The stock was subsequently halted by regulators for clarification of some claims and as a result of the halt was moved to the Pink Sheets in accordance with NASD rules. The company has and continues to cooperate fully with regulators. We are confident that a return to the OTCBB will occur in the not too distant future. Now, with the announcement of Abbott signing on, it not only enhances the validity of the technology, but also bodes well for future deals and the ability for Biocurex to engage in more R&D to further expand its state of the art bio-technology and sector influence. Over the months I've had several emails questioning the validity and viability of both Biocurex and its technology. My answer was always the same: be patient. It still is. We believe that this is only the beginning of the company's technologies, current and future, that will eventually take their place in the forefront of early cancer detection and therapy. As we have oft-said; patience is a virtue, especially in the smallcap market. You want patience? Today's announcement is the culmination of over 20 years of research and development since the RECAF? marker was first discovered.   PRESS RELEASE For Immediate Release ABBOTT AND BIOCUREX ENTER INTO AGREEMENT FOR RECAF? CANCER TECHNOLOGY - An emerging cancer biomarker, RECAF is found on malignant cells from a variety of cancer types and may be useful in the development of new cancer tests - ABBOTT PARK, Ill., and RICHMOND, British Columbia, Mar. 29, 2005 -- Abbott and BioCurex today announced they have entered into a licensing agreement for BioCurex's RECAF? material and technology.  The receptor for alpha-fetoprotein, RECAF has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests.  RECAF is found on malignant cells from a variety of cancer cell types but is absent in most normal and benign cells.  Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others. "Because many cancer deaths may be prevented with early screening and treatment, it's important to develop new cancer tests that could more effectively target a specific type of cancer.  Preliminary studies indicate that RECAF may provide good clinical sensitivity and specificity as a tumor marker," said William Brown, Ph.D., vice president, Diagnostic Assays and Systems Development, Abbott.  "Abbott's goal is to further develop this technology, incorporating it into future tests on our ARCHITECT® system, for use in cancer diagnosis and monitoring." Under terms of the agreement, Abbott obtains worldwide, semi-exclusive rights to commercialize products using BioCurex's RECAF technology.  The agreement includes payment to BioCurex of up-front fees, product development milestones and royalties on any product sales.  Other terms of the agreement were not disclosed. "In terms of cancer detection and treatment, our RECAF technology has the potential to improve patient care due to its ability to differentiate cancer cells from healthy cells.  Abbott is a worldwide leader in diagnostic testing, and we're very excited to be able to work with them on implementing this technology with Abbott's instruments for use in future cancer tests," said Ricardo Moro, M.D., chief executive officer, BioCurex. According to the World Health Organization, more than 10 million people are diagnosed with cancer every year, and it is estimated that there will be 15 million new cases every year by 2020.  The chance of cure increases substantially if cancer is detected early. About BioCurex BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the area of cancer diagnosis, imaging and therapeutics.  To find out more about BioCurex (BOCX.PK), visit www.biocurex.com. About Abbott Abbott has a strong history in cancer diagnostics.  In 1991, Abbott developed the first automated PSA test for use on the IMx® System and has continued to expand cancer test menus across its diagnostic analyzers.  Abbott's innovative genomic tests include Vysis® UroVysion, which aids in diagnosing and monitoring bladder cancer, and PathVysion®, for detecting amplification of the HER-2 gene to aid in determining whether a patient is an appropriate candidate for Herceptin® (trastuzumab) therapy for breast cancer. Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs more than 60,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at www.abbott.com. ______________ Contact: For Abbott Amy Woodworth, 847-935-4755 (Media) or John Thomas, 847-938-2655 (Financial Community) or For BioCurex Inc. Fischer Health Jennifer Brendel, 310-577-7870, Ext. 108 (Media) or Aurelius Consulting Group Inc. Financial Community Dave Gentry, 800-644-6297, Ext. 104 or Chris Bemudaz, 800-644-6297, Ext. 103 or BioCurex Inc., 604-207-9150   We Value Your Feedback Got comments, questions or suggestions? Send 'em on over: Editor@smallcapnetwork.com If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 3525 Del Mar Heights Rd #334 San Diego, CA 92130   Unsubscribe Here D I S C L A I M E R: The SmallCap Digest is an independent electronic publication committed to providing our readers with factual information on selected  publicly traded companies. SmallCap Digest is not a licensed investment professional or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward  maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features for the publication and circulation of the SmallCap Digest or representation on SmallCapNetwork.net.  Likewise, this newsletter is owned by TGR, LLC.  To the degrees enumerated herein,  this newsletter should not be regarded as an independent publication. Visit Here to view our compensation on every company we have ever covered, or visit the following web address:  http://access.smallcapnetwork.com/compensation_disclosure.html for our full compensation disclosure and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts compensation and disclosure. TGR Group LLC has been paid a fee of $25,000 and one million newly issued restricted shares by Biocurex for coverage of the company. Under SEC Rule 144, 570,000 shares of the 1 million newly issued restricted shares are now eligible for sale into the public market. TGR Group has submitted the approriate filings to sell the shares.  In addition, on March 22, 2005, TGR entered into an extended agreement with Biocurex for a fee of 25,000 newly issued restricted shares. Additionally, Some of the companies featured in the SmallCap Digest Newsletter pay an ESP (Electronic Service Provider) fee to an affiliated Technology Company for electronic delivery of this newsletter and other web related technology services. Fees range from $3,000 to $5,000 per month. All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. From time to time TGR Group LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies. The editor, members of the editor's family, and/or entities with  which the editor is affiliated aside from TGR Group LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. The profiles, critiques, and other editorial content of the SmallCap Digest and SmallCapNetwork.net may contain statements that appear forward as it relates to the expected capabilities of the companies mentioned herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF SMALLCAPNETWORK.NET. We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.